Dr. Slamon on the Benefit of Ribociclib Plus Fulvestrant in HR+/HER2- Advanced Breast Cancer

Video

Dennis J. Slamon, MD, PhD, discusses the long-term benefit of ribociclib plus fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer.

Dennis J. Slamon, MD, PhD, director of the Revlon/UCLA Women's Cancer Research Program at Johnson Comprehensive Cancer Center; a professor of medicine; chief of the Division of Hematology/Oncology; executive vice chair of research in the Department of Medicine; and director of clinical/translational research at The University of California, Los Angeles, discusses the long-term benefit of ribociclib (Kisqali) plus fulvestrant (Faslodex) in patients with hormone receptor-positive, HER2-negative advanced breast cancer.

The combination was examined in the phase 3 MONALEESA-3 trial (NCT02422615), which enrolled and randomized 726 patients 2:1 to receive either ribociclib plus fulvestrant, or placebo plus fulvestrant, according to Slamon.

The landmark analysis indicated that the predicted 4 year overall survival rate would be 44.5% in the control arm vs 53.6% in the experimental arm. The predicted difference only increases at 5 years, with 31.1% in the control arm, and 46.0% in the experimental arm. The data have been consistent with longer follow up and patients have been significantly benefitting from the combination of ribociclib and fulvestrant, Slamon concludes.

Related Videos
Sumanta Kumar Pal, MD, FASCO,
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Samilia Obeng-Gyasi, MD, MPH,
Nan Chen, MD
Timothy Yap, MBBS, PhD, FRCP
Parul N Barry, MD,
Angela Jia, MD, PhD, of University Hospitals